BioNTech SE filed its invitation to the 2026 Annual General Meeting on May 15, 2026, proposing to carry forward EUR 6.9 billion 2025 balance sheet profit, expand Supervisory Board to eight members, appoint EY as 2026 auditor, and authorize new EUR 129.5 million share capital.
Key takeaways
Propose carrying forward full EUR 6,901,677,892.10 balance sheet profit from 2025 financial year to new account.
Expand Supervisory Board from 6 to 8 members to enhance oncology, clinical development, and commercialization expertise amid strategic realignment.
Re-elect three current members (Helmut Jeggle, Prof. Dr. Anja Morawietz, Prof. Dr. Rudolf Staudigl) and elect two new (Dr. Susanne Schaffert, Prof. Dr. Iris Loew-Friedrich) to Supervisory Board.
Appoint EY GmbH & Co. KG as auditor and group auditor for 2026 financial year and interim reports through Q1 2027.
Cancel existing Authorized Capital 2025 (remaining EUR 113.8 million) and create new Authorized Capital 2026 up to EUR 129,513,743 until May 15, 2030, with subscription rights exclusions.
Reauthorize Management Board for virtual Annual General Meetings for two years post-registration.